Centogene N.V. (Nasdaq: CNTG), the essential life
science partner for data-driven answers in rare and
neurodegenerative diseases, today announced its unaudited financial
results for the six months ended June 30, 2023. The half year
results are compared to the same periods in the prior year, unless
otherwise specified, and reflect revisions as described below.
“CENTOGENE’s transformation as the essential
partner for rare and neurodegenerative diseases is well underway.
We are continuing to deliver against our goals in our core
Diagnostics and Pharma segments,” stated Kim Stratton, Chief
Executive Officer at CENTOGENE. “In Diagnostics, we have again
showed double-digit growth in the first half of 2023 compared to
the first half of 2022, with strong execution on our differentiated
products, such as NEW CentoGenome®, CentoXome®, and MOx, our
multiomic portfolio. This also validates our approach to invest in
focus regions, with strong growth in Europe and Latin America. The
first half of the year also showed a significant increase of 20% in
our Pharma segment, confirming our growth trajectory. We have now
fully resourced the Pharma commercial team and will continue to
build our pipeline for 2023 and 2024. We are pleased to reaffirm
our guidance for full year 2023 revenue growth between 10% to
15%.”First Half 2023 - Financial Highlights
- Total revenues for the first half of
2023 increased by 15.1% to €24.6 million, reflecting strong growth
in both the Diagnostics and Pharma segments, compared to €21.4
million in the first half of 2022
- Diagnostics segment revenues
increased by 12.7% to €16.3 million in the first half of 2023
compared to the first half of 2022. This solid-double-digit growth
is primarily related to an increase of 30% in test requests for
CentoXome® (CENTOGENE’s proprietary Whole Exome Sequencing (“WES”))
and CentoGenome® (CENTOGENE’s proprietary Whole Genome Sequencing
(“WGS”)). Contributions were also achieved through upselling 49% of
CentoXome® and CentoGenome® orders to MOx (CENTOGENE’s portfolio of
multiomic testing solutions) in the first half of 2023. Gross
margins in the segment were 32% compared to 35% in the first half
of 2022, primarily driven by a newly agreed, one-time discounted
payment from a Diagnostics customer with a history of significant
payment delays. This has been partially offset by technology and
operational efficiency gains
- Pharma segment revenues continued on
a growth trajectory, with a significant increase of 20.3% to €8.3
million in the first half of 2023 compared to €6.9 million in the
first half of 2022. This growth was primarily driven by
observational studies for patient finding and market access in
collaboration with global pharma partners to support clinical
development stage projects in rare and neurodegenerative disorders.
Gross margins in the segment were 45% in the first half of 2023
compared to 49% in the first half of 2022, reflecting the ramp-up
of the Pharma commercial team and the addition of dedicated
personnel in lab operations to align with the growth
trajectory
- The operating loss decreased to
€21.3 million in the first half of 2023, from €21.4 million in the
first half of 2022. This reflects an improvement in gross profit of
6.5%, with a 24.5% reduction in research and development (R&D)
expenses partially being offset by higher selling expenses to drive
commercial efforts in both Pharma and Diagnostics
- Total segment adjusted EBITDA
(reflecting the Diagnostics and Pharma segment) was €2.9 million in
the first half of 2023, a decrease of 45.3% compared to €5.3
million in the first half of 2022, mainly reflecting the fully
resourced Pharma commercial team as a result of the shift of
resources from corporate functions into directly business-related
roles. In line with this, corporate expenses decreased by 14% to
€18.4 million
- Cash and cash equivalents were €14.2
million as of June 30, 2023, compared to €36.0 million as of
December 31, 2022. The underlying cash burn has decreased in the
first half of 2023 compared to the first half of 2022; however,
this has been partially offset by one-off investments
Kim Stratton added, “We reached a significant
milestone by signing the strategic partnership with Lifera, a
biopharmaceutical company wholly-owned by the Public Investment
Fund (“PIF”) of Saudi Arabia, in June 2023. Lifera’s investment
secures CENTOGENE a committed strategic partner for the future, and
the overall partnership forms a pathway to achieving sustainable
growth and profitability for CENTOGENE. This partnership is a
testament to CENTOGENE’s extensive know-how and leading position in
rare diseases.”
Commenting on the financial performance, Miguel
Coego, Chief Financial Officer at CENTOGENE noted, “In the first
half of 2023, we have continued to reduce our general and
administrative expenses (“G&A”) by 18% (excluding Share Base
Payments) and research and development expenses (“R&D”) by
24.5%. The positive impact has been somewhat offset by one-off
expenses, such as restructuring costs, which will reduce our
overall cost base going forward. We have prioritized resourcing our
key revenue drivers. We will continue to prioritize growth,
margins, and cost diligence and drive sustainable financial
performance.”
Recent Business Highlights
Corporate
- Announced strategic collaboration
with Lifera, a biopharmaceutical company wholly-owned by the PIF,
with the formation of a joint venture (JV) to increase local and
regional access and rapid delivery of world-class multiomic testing
to patients in Saudi Arabia and countries of the Gulf Cooperation
Council (GCC). Under the terms of the collaboration, CENTOGENE is
planning to also receive a $30 million mandatory convertible loan
from Lifera, as well as up to approximately $50 million in JV
upfront payment and performance-related milestones. The transaction
is expected to close and fund within the next 45 days
- Added approximately 50,000
individuals to the CENTOGENE Biodatabank in the first half of 2023,
with over 800,000 patients from over 120 highly diverse countries
represented in total, over 70% of whom are of non-European descent.
This includes some of the world’s largest disease-specific cohorts,
such as Parkinson’s disease, with over 15,000 patients
- Authored 12 peer-reviewed scientific
publications in the first half of 2023, unlocking insights into
Parkinson’s disease, Gaucher disease, cystic fibrosis transmembrane
conductance regulator (CFTR)-related disease, TOR1A-related
disorders, spastic paraplegia, renal hypouricemia, colorectal
carcinomas, and other neurodevelopmental disorders
- Announced the approval of all
resolutions tabled at the 2023 Annual General Meeting, including
the appointment of Prof. Dr. Peter Bauer as a member of the
Management Board of the Company, as well as the appointment of Mary
Sheahan and the reappointment of Peer Schatz as members of the
Supervisory Board of the Company
Pharma
- 38 active collaborations as of June
30, 2023; 18 contracts were signed in the first half of 2023, 16 of
which were with existing customers
- Extended Takeda partnership to March
2024 to continue providing access to genetic testing for patients
with lysosomal storage disorders
- Entered strategic collaborations
with IQVIA and Premier Research to extend strategy and expand
commercialization model with pharma partners via Contract Research
Organizations (CROs)
- Leading three observational studies
for patient identification and characterization in collaboration
with our pharma partners in rare and neurodegenerative disorders,
including, alongside Denali Therapeutics, the ROPAD Study, the
world’s largest observational study on Parkinson’s disease genetics
with over 15,000 enrolled patients to date. Patients enrolled in
ROPAD and identified with LRRK2 genetic variations may be eligible
for participation in ongoing interventional clinical studies
Diagnostics
- Reported order intake of
approximately 39,878 test requests in our Diagnostics segment in
the first half of 2023, representing an increase of approximately
22.2% as compared to 32,623 test requests in the first half of
2022
- Published study in the European
Journal of Human Genetics revealing unique genetic variants in
world's largest Niemann-Pick type C1 disease cohort
- Published a study in the Diagnostics
journal establishing lyso-Gb1 (glucosylsphingosine) as a predictive
biomarker
- Launched NEW CentoGenome®, the
world's most comprehensive Whole Genome Sequencing tool for
diagnosis of rare and neurodegenerative diseases, which now detects
Copy Number Variations associated with spinal muscular atrophy, as
well as complex disease-causing variants associated with Gaucher
disease and susceptibility to GBA1-related Parkinson's disease
- Launched together with TWIST
Bioscience three Next Generation Sequencing target enrichment
panels, Twist Alliance CNTG Exome, Twist Alliance CNTG Rare Disease
Panel, and Twist Alliance CNTG Hereditary Oncology Panel, to
support rare disease and hereditary cancer research and support
diagnostics
- Integrated Illumina’s new NovaSeq X
Plus Sequencer into our state-of-the-art, CAP/CLIA accredited
laboratory in Rostock, Germany, to further optimize throughput,
scale, and cost efficiencies
First Half 2023 Financial
Summary
Our total revenues for the first half of 2023
were €24,624 thousand, representing an increase of €3,235 thousand,
or 15.1%, as compared to €21,405 thousand for the first half of
2022.
Revenues from our Pharmaceutical segment were
€8,286 thousand for the first half of 2023, representing an
increase of €1,398 thousand, or 20.3%, from €6,888 thousand for the
first half of 2022. Our partnership agreements are structured on a
fee-per-sample basis, milestone basis, fixed fee basis, or a
combination thereof. The increase was primarily due to increased
activity in the clinical development and market access and
expansion of our pharmaceutical partners.
During the first half of 2023, we entered into
nine new collaborations and successfully completed twelve
collaborations resulting in a total of 38 active collaborations at
June 30, 2023, compared to 41 active collaborations at December 31,
2022 and 45 active collaborations as of June 30, 2022. Revenues
from our new collaborations amounted to €1,750 thousand, for the
first half of 2023.
Revenues from our Diagnostics segment were
€16,338 thousand for the first half of 2023, an increase of €1,837
thousand, or 12.7%, from €14,501 thousand for the first half of
2022 due to a 22.2% increase in test requests received comparing to
the first half year of 2022.
Total revenues from WES and WGS for the first
half of 2023 amounted to €9,185 thousand, representing an increase
of 17.0% as compared to €7,853 thousand for the first half of 2022.
The total number of WES and WGS test requests received in the
Diagnostics segment for the first half of 2023 was approximately
14,704, representing an increase of 30.5% as compared to
approximately 11,226 test requests received for the first half of
2022.
Cost of sales increased by €2,692 thousand, or
20.7%, to €15,728 thousand for the first half of 2023, from €13,036
thousand for the first half of 2022. Cost of sales for the first
half of 2023 represented 63.9%, of total revenue, representing an
increase of 2.9% percentage points, respectively, as compared to
60.9%, first half of 2022. The overall increase for the first half
of 2023 was mainly driven by an increase of €1,819 thousand on
consumable expenses for lab materials.
As a result of the above factors, our gross
profit for the first half of 2023, increased by €543 thousand, or
6.5%, to €8,896 thousand from €8,353 thousand for the first half of
2022.
Research and development expenses decreased by
€2,220 thousand, or 24.5%, to €6,851 thousand for the first half of
2023, from €9,071 thousand for the first half of 2022. The decrease
is mainly driven by realization of organizational efficiencies and
savings in external expenses for data storage & processing.
General administrative expenses decreased by
€112 thousand, or 0.6%, to €17,172 thousand for the first half of
2023, from €17,284 thousand for the first half of 2022. The
decrease is principally due to the reduction in personnel costs due
to cost savings driven by the restructuring and organizational
efficiencies that was initiated in the last quarter of 2021.
However, excluding the Share Based Payments
fully allocated to G&A, the underlying G&A reduction is 18%
or €3,418 thousand compared to the first half of 2022.
Selling expenses for the first half of 2023 were
€6,699 thousand, representing an increase of €1,507 thousand, or
29.0%, as compared to €5,192 thousand for the first half of 2022.
The increase for the first half of 2023 was principally due to the
reinforcement of the commercial organization as well as increases
in sales commission for external distribution partners.
Impairment expenses for the first half of 2023
increased by €496 thousand, to €496 thousand as compared to nil
incurred for the first half of 2022, while a gain on reversal of
financial asset impairment was recorded for the first half of 2022
of €937 thousand, mainly driven by the MENA region.
Other operating income decreased by €65
thousand, or 4.7%, to €1,325 thousand for the first half of 2023,
from €1,390 thousand for the first half of 2022, principally due to
a lower grant income released during the period.
Other operating expenses which relate to
currency losses decreased by €251 thousand, to €256 thousand in the
first half of 2023, compared to €507 thousand for the first half of
2022.
The change in net financial costs by €1,693
thousand, for the first half of 2023 is mainly due to the increased
interest expense and unrealized foreign exchange impact of the
Oxford Loan Facility, and the change in the valuation of warrants
between both periods.
As a result of the factors described above, our
loss before taxes from continuing operations for the first half of
2023 was €24,443 thousand representing a decrease of €1,554
thousand, from a loss before taxes from continuing operations of
€22,889 thousand for the first half of 2022.
Adjusted EBITDA from our Pharmaceutical segment
for the first half of 2023 was €1,565 thousand representing a
decrease of €1,006 thousand, as compared to €2,571 thousand for the
first half of 2022. The decrease was primarily attributable to the
reinforcement of the commercial department under the Pharmaceutical
segment.
Adjusted EBITDA from our Diagnostics segment for
the first half of 2023 was 1,306 thousand, representing a decrease
of €1,413 thousand, as compared to €2,719 thousand for the first
half of 2022. The decrease is mainly due to the increase in
consumable expenses on approximately €1,601 thousand for the first
half of 2023.
2023 Financial Guidance
The Company reaffirms its guidance for 2023
annual revenue growth between 10-15% versus fiscal year 2022
revenues as revised.
To view the full SEC filing, visit:
https://investors.centogene.com/financials-and-filings/sec-filings
About CENTOGENE
CENTOGENE’s mission is to provide data-driven,
life-changing answers to patients, physicians, and pharma companies
for rare and neurodegenerative diseases. We integrate multiomic
technologies with the CENTOGENE Biodatabank – providing dimensional
analysis to guide the next generation of precision medicine. Our
unique approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been
offering rapid and reliable diagnosis – building a network of
approximately 30,000 active physicians. Our ISO, CAP, and CLIA
certified multiomic reference laboratories in Germany utilize
Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and
Metabolomic datasets. This data is captured in our CENTOGENE
Biodatabank, with over 800,000 patients represented from over 120
highly diverse countries, over 70% of whom are of non-European
descent. To date, the CENTOGENE Biodatabank has contributed to
generating novel insights for more than 285 peer-reviewed
publications.
By translating our data and expertise into
tangible insights, we have supported over 50 collaborations with
pharma partners. Together, we accelerate and de-risk drug
discovery, development, and commercialization in target & drug
screening, clinical development, market access and expansion, as
well as offering CENTOGENE Biodatabank Licenses and Insight Reports
to enable a world healed of all rare and neurodegenerative
diseases.
To discover more about our products, pipeline,
and patient-driven purpose, visit www.centogene.com and follow
us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Statements contained herein that are not clearly historical in
nature are forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “potential,” “predict,” “objective” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth, execute our
business strategy and enter into new client relationships, our
dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our continued ongoing compliance with
covenants linked to financial instruments, our requirement for
additional financing, and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on May 16, 2023,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
CONTACT
CENTOGENE
Melissa HallCorporate Communications
Press@centogene.com
Lennart StreibelInvestor Relations
IR@centogene.com
Centogene N.V.Unaudited
consolidated statements of comprehensive loss (in
EUR k)
|
|
|
|
|
|
|
|
|
|
|
For the six months ended June 30 |
|
|
|
|
2023 |
|
|
2022 |
|
Revenue |
|
|
|
24,624 |
|
|
21,389 |
|
Cost of sales |
|
|
|
15,728 |
|
|
13,036 |
|
Gross
profit |
|
|
|
8,896 |
|
|
8,353 |
|
Research and development
expenses |
|
|
|
6,851 |
|
|
9,071 |
|
General administrative
expenses |
|
|
|
17,172 |
|
|
17,284 |
|
Selling expenses |
|
|
|
6,699 |
|
|
5,192 |
|
Impairment of financial
assets |
|
|
|
496 |
|
|
— |
|
Gain on reversal of financial
asset impairment |
|
|
|
— |
|
|
919 |
|
Other operating income |
|
|
|
1,325 |
|
|
1,390 |
|
Other operating expenses |
|
|
|
256 |
|
|
507 |
|
Operating
loss |
|
|
|
(21,253 |
) |
|
(21,392 |
) |
Changes in fair value of
warrants |
|
|
|
(442 |
) |
|
1,639 |
|
Interest and similar income |
|
|
|
849 |
|
|
1 |
|
Interest and similar expense |
|
|
|
3,597 |
|
|
3,137 |
|
Financial costs, net |
|
|
|
(3,190 |
) |
|
(1,497 |
) |
Loss before taxes from
continuing operations |
|
|
|
(24,443 |
) |
|
(22,889 |
) |
Income tax expenses |
|
|
|
13 |
|
|
179 |
|
Loss for the period from
continuing operations |
|
|
|
(24,456 |
) |
|
(23,068 |
) |
Net income from discontinued
operations, net of tax |
|
|
|
— |
|
|
6,140 |
|
Loss for the
period |
|
|
|
(24,456 |
) |
|
(16,928 |
) |
Other comprehensive
income/(loss), all attributable to equity holders of the
parent |
|
|
|
(148 |
) |
|
23 |
|
Total comprehensive
loss |
|
|
|
(24,604 |
) |
|
(16,905 |
) |
Attributable to: |
|
|
|
|
|
|
Equity holders of the parent |
|
|
|
(24,604 |
) |
|
(16,658 |
) |
Non‑controlling interests from
continuing operations |
|
|
|
— |
|
|
— |
|
Non‑controlling interests from
discontinued operations |
|
|
|
— |
|
|
(247 |
) |
|
|
|
|
(24,604 |
) |
|
(16,905 |
) |
Net loss per share -
Basic and diluted from (in EUR) |
|
|
|
|
|
|
Continuing operations |
|
|
|
(0.88 |
) |
|
(0.88 |
) |
Loss attributable to parent |
|
|
|
(0.88 |
) |
|
(0.64 |
) |
|
|
|
|
|
|
|
Centogene N.V.Unaudited consolidated
statements of financial position (in EUR
k)
|
|
|
|
|
|
|
|
Assets |
|
|
|
June 30, 2023 |
|
Dec 31, 2022 |
|
|
|
|
|
|
|
|
|
Non‑current
assets |
|
|
|
|
|
|
|
Intangible assets |
|
|
|
8,180 |
|
7,400 |
|
Property, plant and equipment |
|
|
|
6,244 |
|
6,808 |
|
Right-of-use assets |
|
|
|
15,370 |
|
15,351 |
|
Derivatives assets |
|
|
|
276 |
|
510 |
|
Other assets |
|
|
|
2,911 |
|
2,911 |
|
|
|
|
|
32,981 |
|
32,980 |
|
Current
assets |
|
|
|
|
|
|
|
Inventories |
|
|
|
2,129 |
|
1,819 |
|
Trade receivables and contract assets |
|
|
|
17,919 |
|
16,548 |
|
Other assets |
|
|
|
4,710 |
|
5,514 |
|
Cash and cash equivalents |
|
|
|
14,153 |
|
35,951 |
|
|
|
|
|
38,911 |
|
59,832 |
|
|
|
|
|
71,892 |
|
92,812 |
|
|
|
|
|
|
|
|
Equity and liabilities |
|
|
|
June 30, 2023 |
|
Dec 31, 2022 |
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
Issued capital |
|
|
|
3,412 |
|
|
3,307 |
|
Capital reserve |
|
|
|
146,184 |
|
|
145,369 |
|
Accumulated deficit and other reserves |
|
|
|
(164,818 |
) |
|
(141,265 |
) |
|
|
|
|
(15,222 |
) |
|
7,411 |
|
Non‑current
liabilities |
|
|
|
|
|
|
Non‑current loans |
|
|
|
39,634 |
|
|
40,051 |
|
Lease liabilities |
|
|
|
13,459 |
|
|
13,125 |
|
Deferred tax liabilities |
|
|
|
25 |
|
|
35 |
|
Government grants |
|
|
|
6,099 |
|
|
6,687 |
|
Derivatives liabilities |
|
|
|
205 |
|
|
376 |
|
Warrant liability |
|
|
|
689 |
|
|
260 |
|
Other liabilities |
|
|
|
101 |
|
|
202 |
|
|
|
|
|
60,212 |
|
|
60,736 |
|
Current
liabilities |
|
|
|
|
|
|
Government grants |
|
|
|
1,173 |
|
|
1,263 |
|
Current loans |
|
|
|
4,501 |
|
|
4,635 |
|
Lease liabilities |
|
|
|
2,311 |
|
|
2,311 |
|
Liabilities from income taxes |
|
|
|
88 |
|
|
89 |
|
Trade payables |
|
|
|
6,951 |
|
|
6,317 |
|
Other liabilities |
|
|
|
11,878 |
|
|
10,050 |
|
|
|
|
|
26,902 |
|
|
24,665 |
|
|
|
|
|
71,892 |
|
|
92,812 |
|
|
|
|
|
|
|
|
|
|
Centogene N.V.Unaudited consolidated
statements of cash flows (in EUR k)
|
|
|
|
|
|
|
|
|
|
|
For the six months ended June 30 |
|
|
|
|
2023 |
|
2022 |
Operating
activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before taxes from continuing operations |
|
|
|
(24,443 |
) |
|
(22,889 |
) |
Income before taxes from
discontinued operations |
|
|
|
— |
|
|
6,153 |
|
Loss before taxes |
|
|
|
(24,443 |
) |
|
(16,736 |
) |
|
|
|
|
|
|
|
Adjustments to
reconcile loss to cash flow from operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and depreciation |
|
|
|
3,801 |
|
|
5,958 |
|
Interest income |
|
|
|
(849 |
) |
|
(1 |
) |
Interest expense |
|
|
|
3,575 |
|
|
3,137 |
|
Expected credit loss allowances on trade receivables and contract
assets |
|
|
|
496 |
|
|
— |
|
Gain on revaluation of credit loss allowance on trade receivables
and contract assets |
|
|
|
— |
|
|
(919 |
) |
Gain on disposal of property, plant and equipment |
|
|
|
(24 |
) |
|
(683 |
) |
Share‑based payment (true up)/ expenses |
|
|
|
1,920 |
|
|
(1,386 |
) |
Fair value adjustments of warrants |
|
|
|
442 |
|
|
(1,639 |
) |
Tax expense |
|
|
|
— |
|
|
192 |
|
Other non‑cash items |
|
|
|
(392 |
) |
|
(580 |
) |
|
|
|
|
|
|
|
Changes in operating
assets and liabilities |
|
|
|
|
|
|
Inventories |
|
|
|
(310 |
) |
|
1,715 |
|
Trade receivables and contract assets |
|
|
|
(1,867 |
) |
|
8,849 |
|
Other assets |
|
|
|
804 |
|
|
1,499 |
|
Trade payables |
|
|
|
634 |
|
|
(6,495 |
) |
Other liabilities |
|
|
|
1,726 |
|
|
(8,060 |
) |
|
|
|
|
|
|
|
Thereof cash flow (used in)
continuing operating activities |
|
|
|
(14,487 |
) |
|
(22,504 |
) |
Thereof cash flow from
discontinued operating activities |
|
|
|
— |
|
|
7,355 |
|
Net cash flow (used
in) operating activities |
|
|
|
(14,487 |
) |
|
(15,149 |
) |
|
|
|
|
|
|
|
Investing
activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for investments in
intangible assets |
|
|
|
(2,143 |
) |
|
(151 |
) |
Cash paid for investments in
property, plant and equipment |
|
|
|
(25 |
) |
|
(843 |
) |
Cash received for disposal of
property, plant and equipment |
|
|
|
24 |
|
|
779 |
|
|
|
|
|
|
|
|
Thereof cash flow (used in)
continuing investing activities |
|
|
|
(2,144 |
) |
|
(994 |
) |
Thereof cash flow from
discontinued investing activities |
|
|
|
- |
|
|
779 |
|
Cash flow (used in)
investing activities |
|
|
|
(2,144 |
) |
|
(215 |
) |
|
|
|
|
|
|
|
Financing
activities |
|
|
|
|
|
|
Cash received from issuance of
shares |
|
|
|
— |
|
|
12,058 |
|
Cash received from issuance of
warrants |
|
|
|
— |
|
|
2,833 |
|
Cash received from loans |
|
|
|
3,604 |
|
|
21,695 |
|
Cash repayments of loans |
|
|
|
(3,906 |
) |
|
(148 |
) |
Cash repayments of lease
liabilities |
|
|
|
(1,319 |
) |
|
(2,241 |
) |
Interest received |
|
|
|
7 |
|
|
1 |
|
Interest paid |
|
|
|
(3,575 |
) |
|
(3,137 |
) |
|
|
|
|
|
|
|
Thereof net cash flow
from/(used in) continuing financing activities |
|
|
|
(5,189 |
) |
|
31,542 |
|
Thereof net cash flow (used
in) discontinued financing activities |
|
|
|
- |
|
|
(481 |
) |
Net cash flow from/
(used in) financing activities |
|
|
|
(5,189 |
) |
|
31,061 |
|
|
|
|
|
|
|
|
Changes in cash and cash
equivalents |
|
|
|
(21,820 |
) |
|
15,697 |
|
Cash and cash equivalents at
the beginning of the period |
|
|
|
35,951 |
|
|
17,818 |
|
Effect of movements in
exchange rates on cash held |
|
|
|
22 |
|
|
— |
|
Cash and cash equivalents at
the end of the period |
|
|
|
14,153 |
|
|
33,515 |
|
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2024 to May 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From May 2023 to May 2024